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Comparison of a Two-Lead, Computerized, Resting ECG Signal Analysis
Device, the Multifunction-CardioGram (MCG), to Coronary Angiography or
MDCT, SPECT for the Detection of Revalent Coronary Artery Stenosis
Makoto Kadotani1
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BACKGROUND MCG (Multifunction CardioGram) is new technology
developed by Premier Heart in USA. Analyze cardiovascular function
(mainly ischemia) by frequency digitalized ECG data which is obtained
approximately 7 minutes of 2 leads (II and V5) of resting ECG. (Total
testing time is 20-30 minutes.) Data is transmitted through the internet
to the data center in the USA and analyzed automatically. “Analyze” is
categorized as amedical device in the USA (Class I). CPT code is obtained
(j applicable health insurance). In Japan, it is not categorized asmedical
device. (Not applicable pharmaceutical jurisprudence and insurance).
MCG analyzes patient’s information, comparing to a database of
over 40.000 patients’ electrocardiograms at rest. A numeric score is
assigned on this analysis representing the likelihood and severity of
CAD, using a score from 0 to 20, with a score of 4.0 or higher indi-
cating CO (coronary obstruction).
The study group consists of 95 patients, (mean age at 67.49.3,
Male; 69 patients and Female; 26 patients), who are planning to or
underwent CAG or MDCT, SPECT.
For these patients, using MCG testing, with the data transferred
over the internet to Premier Heart in New York for analysis, sensitivity
and speciﬁcity for patients of stenosis was  75%.
METHODS MCG analyzes patient’s information, comparing to a data-
base of over 40.000 patients’ electrocardiograms at rest. Obtain
resting ECG data of the patient with stable condition. Total time will
be approximately 20-30 minutes including resting time before testing.
Time for analyze will be a few minutes after transmitting data. A
numeric score is assigned on this analysis representing the likelihood
and severity of CAD, using a score from 0 to 20, with a score of 4.0 or
higher indicating CO (coronary obstruction). We performed fully
informed consent. After that, we performed MCG test, 117cases. The
study group consists of 95 patients, (mean age at 67.49.3, Male; 69
patients and Female; 26 patients), who are planning to or underwent
CAG or MDCT, SPECT. For these patients, using MCG testing, with the
data transferred over the internet to Premier Heart in New York for
analysis, sensitivity and speciﬁcity for patients of stenosis was  75%.
22cases were excluded. The reasons were MCG ECG quality level all
poor, test after PCI, CAG or SPECT negative.
RESULTS Baseline characteristics were no different between 2groups,
MCG scoreS4.0 and ＜4.0. At the cut-off of 4.0 indicating CO, accu-
racy is 62.1%, sensitivity is 65.3%, speciﬁcity is 52.2%, PPV is 81.0%,
and NPV is 32.4%.
However revisiting the cut-off to 3.0 to reﬂect indication of CO, the
data reﬂects accuracy is 70.5%, sensitivity is 83.3%, speciﬁcity is
30.4%, PPV is 78.9%, and NPV is 36.8%. Despite cut-off being 4.0,the
outcome showed increased reliability after including the MCG session
analysis, with accuracy at 78.9%,sensitivity at 95.8%,speciﬁcity at
26.1%,PPV at 80.2% and NPV at 66.7%.
The cases tested by all of CAG/SPECT/MCG: n¼86
1. By setting only 75% S CAG stenosis was positive; compare the
ROC of SPECT and MCG with CAG. Positive: 71 cases Negative: 15
cases (CAG result only, excluding OMI, etc.) 2. Applying Cutoff score
4þ 4 secondary and tertiary index.
1. The 75%SCAG stenosiswas foundwhenSPECTwas positive andFalse
Positive case for SPECT was 0. However, SPECT can’t detect False Negative
19patient (27%) and the number of True Positive cases was lower than the
MCG.(67vs 52) 2. The MCG had more False Positive than True Negative.
However, within the False Positive patient heart abnormality such as OMI,
VSAP, wall motion abnormality or heart failure patients were included and
these abnormality might have contributed to FP. 3. In conclusion, the MCG
showed a high accuracy for screening coronary artery disease.
CONCLUSION Subjects included in the trial were ambulatory patients
who presented to their physicians for evaluation with either Coronary
Angiography or SPECT-MPI.
This might inﬂuence on the high accuracy .sensitivity and PPV of
this study.
Considering the use in the health checkup center, further study
targeting for low risk population might be important to ﬁnd out the
relation between CAD risk factors and the MCG score within low risk
population. Optima medical therapy is important method for treating
coronary artery disease with a exception of acute coronary syndromesor conﬁrmed is chemic patient. Also it is a very important treatment as
a primary and secondary prevention for CAD. However, there is an
issue with optimal medical therapy that is difﬁcult to get consensus
especially from the symptomatic patient.
Through this study it was suggested that the MCG test, which is an
easy noninvasive test with high accuracy for CAD risk, might motivate
patient toward optimal medical therapy from the primary prevention
stage. Through this study it was suggested that the MCG test is very
useful for screening CAD risk of S 75% stenosis. The MCG test is
noninvasive test and can be applied regardless patient characteristic
such as age, kidney function and ADL.
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BACKGROUND Hemodialysis ﬁstulas are surgically created communi-
cations between native artery and vein in an extremity. Many patients
who are not candidates for renal transplantation are dependent on
hemodialysis for their lifetime resulting in long-term need for use of
dialysis access. 25% of hospital admissions in the dialysis population
have been attributed to vascular access problems, including ﬁstula
malfunction and thrombosis. Historically, native ﬁstula malfunction
and thrombosis were treated by using surgical thrombectomy and
revision, resulting in the eventual exhaustion of the veins and the need
to create a new access. We have treated the acute av ﬁstula thrombosis
with intra-arterial thrombolysis and report the data.
METHODS The study period was 1year from Jan 2013-2014. A total of 48
ESRD patients onmaintenance hemodialysis were included. Thrombosis of
AVF was documented by Doppler and conﬁrmed by Fistulogram. Intra-
arterial thrombolysiswas done through femoral arterial access with a pigtail
catheter inserted in to the brachial artery for brachiocephalic AVF and into
radial artery just after bifurcation of the brachial artery for radio-cephalic
AVF. Inj. Streptokinase was given as a Bolus of 2.5lakh units followed by a
maintenance dose of 1 lakh units/hour for 24 to 48hours. Check ﬁstulogram
was done after 24hrs. Procedural success reafﬁrmed by performing dialysis
in successful patients.
RESULTS The Mean age of patients was 4415.73years (Range:18-
62years). Angiography was suggestive of thrombosis at juxtTCTAP
A-anastomotic (n¼12), arterial (n¼12) and venous (n¼24) site. Proce-
dural success with at least one dialysis session was noted in 50% of
the patients (24 of 48 patients). Two patients required re-intervention
after 6 months. One ADPKD patient had cyst hemorrhage requiring
blood transfusion who subsequently improved. Four minor compli-
cations like hematemesis (n¼2), and bleeding from the site of cathe-
terization (N¼2) were noted.
S46 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 5 , N O . 1 7 , S U P P L S , 2 0 1 5CONCLUSION Intraarterial Thrombolysis with Streptokinase for acute
AV ﬁstula thrombosis is a relatively cheap, safe option with an overall
success rate of about 58-60% in our series. For arterial and juxtTCTAP
A-anastomotic site ﬁstula thrombosis the success rate is 75%. The
complication rate is minimal.
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BACKGROUND Venoartrial extracorporeal membrane oxygenation
(ECMO) has been used in myocardial failure because of acute
myocardial infarction; myocarditis; decompensated cardiomyopathy;
or intractable arrhythmia to provide immediate cardiac and respira-
tory support. However, persistent left ventricular (LV) dysfunction
and high afterload from arterial cannula gradually lead to elevated LV
end-diastolic pressure, left atrial (LA) pressure, and severe pulmonary
edema. Wall stress and oxygen consumption of left ventricle (LV)
increase, recovery of LV function and weaning from ECMO will be
delayed.
Prompt LA decompression in this setting is important to minimize
LA/LV dilatation, to resolve severe pulmonary edema, and to enhance
LV recovery. LA decompression can be achieved by balloon atrial
septostomy, combined blade and balloon atrial septostomy, tran-
septal/transaortic LV sheath, transaortic pigtail LV drain, surgical LA/
LV vent and transseptal cannula incorporated into the ECMO. Inoue
balloon was specially designed for percutaneous transvenous balloon
mitral valvuloplasty. Persistent atrial septal defect was a well-known
complication of such a procedure. It has been applied in balloon atrial
septostomy (BAS) in severe persistent pulmonary hypertension.
Herein we reported six cases of Inoue balloon catheter atrial septos-
tomy during ECMO in 2012, with satisfactory (gratifying) decompres-
sion of LA. To the best of our knowledge, BAS using an Inoue balloon
for such an indication has not yet been reported.METHODS Institutional review board approval was obtained for
analyzing patient demographics, catheterization reports, angiograms,
echocardiograms, chest radiographs, ECMO ﬂow data, and inpatient
charts. All patients on ECMO undergoing LA decompression between
Jan 2012 and Dec 2012 were identiﬁed. In total, six ECMO patients
underwent Inoue balloon BAS. Informed consent was obtained for all
procedures.
All six procedures were performed in the cardiac catheterization
laboratory under ﬂuoroscopic guidance. All were performed via the
femoral vein. Transseptal puncture was performed by Brocken-
borough needle loaded in Mullin sheath. We performed the puncture
mainly using biplane ﬂuoroscopic guidance. Position of the aortic
valve was identiﬁed by its calciﬁcation or by the pigtail catheter
placed in the non-coronary aortic sinus from femoral artery, Tip of the
needle was directed posteriorly on true lateral view and between 4\’o
and 5 o\’clock positions on AP view. After entering the LA, conﬁrmed
by injection of contrast through the needle, Mullin sheath was
advanced across the interatrial septum and then the needle was
removed. A stainless steel PTMC guidewire was inserted through the
sheath into LA. After the sheath was removed, puncture wound and
subcutaneous tissue and the interatrial septum were dilated by a 11F
PTMC dilator. A 24mm or 26mm Inoue balloon catheter was then
inserted to cross the IAS into LA. After it was half inﬂated, it was pull
back till distal balloon leaning against the IAS, and then it was fully
inﬂated. Indentation of IAS on the waist of the balloon was identiﬁed
and then disappeared after fully inﬂation.
